SCHEMBL5545806

SCHEMBL5545806

CCOC(=O)CCCc1ccc([O])cc1

nearest known ligand 0.60

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
CYP4F2 P78329 3/20 0.60
CYP4A11 Q02928 3/20 0.60
CYP4Z1 Q86W10 3/20 0.59
CYP4F11 Q9HBI6 1/20 0.59
CYP4F12 Q9HCS2 1/20 0.59
ALOX5 P09917 2/20 0.57
MAPK1 P28482 2/20 0.53
GAA P10253 1/20 0.53
NPSR1 Q6W5P4 1/20 0.53
TDP1 Q9NUW8 1/20 0.53
FAAH O00519 1/20 0.48
CYP1A2 P05177 2/20 0.47
CYP3A4 P08684 1/20 0.47
CYP2D6 P10635 1/20 0.47
CYP2C9 P11712 1/20 0.47
CYP2C19 P33261 1/20 0.47
SMN1; SMN2 Q16637 1/20 0.47
ABCB1 P08183 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5542104 0.95 CYP4Z1 (0.60) CYP4F2CYP4A11CYP4Z1CYP4F11CYP4F12
SCHEMBL5545484 0.93 CYP4Z1 (0.59) CYP4F2CYP4A11CYP4Z1CYP4F11CYP4F12
SCHEMBL5544351 0.93 CYP4Z1 (0.59) CYP4F2CYP4A11CYP4Z1CYP4F11CYP4F12
SCHEMBL5543917 0.89 CYP4F2 (0.74) CYP4F2CYP4A11CYP4Z1CYP4F11CYP4F12
SCHEMBL10289874 0.88 CYP4F2 (0.62) CYP4F2CYP4A11CYP4Z1CYP4F11CYP4F12
SCHEMBL765000 0.88 CYP4F2 (0.62) CYP4F2CYP4A11CYP4Z1CYP4F11CYP4F12
SCHEMBL765847 0.88 CYP4F2 (0.62) CYP4F2CYP4A11CYP4Z1CYP4F11CYP4F12
SCHEMBL5050631 0.86 CYP4F2 (0.60) CYP4F2CYP4A11CYP4Z1CYP4F11CYP4F12
SCHEMBL22334798 0.86 CYP4F2 (0.65) CYP4F2CYP4A11CYP4Z1CYP4F11CYP4F12
SCHEMBL9671800 0.86 CYP4Z1 (0.65) CYP4F2CYP4A11CYP4Z1CYP4F11CYP4F12

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1555267-B1 2,3-DIHYDRO-6-NITROIMIDAZO[2,1-b]OXAZOLES OTSUKA PHARMA CO LTD (JP) 2013-01-16 EP disclosed
US-7262212-B2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2007-08-28 US disclosed
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2006-05-04 US disclosed
EP-1555267-A1 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-b OXAZOLES OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2005-07-20 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles NR2C2, NR4A3, NR4A2 CYP4F2 954/4885CYP4A11 1804/4885CYP4Z1 1854/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.